Navigation Links
Tiens Biotech Group (USA) Reports First Quarter Results
Date:5/17/2010

38,037 11,236,501 Total non current liabilities 11,238,037 11,236,501 Total liabilities 49,886,084 45,334,533 EQUITY: Shareholders' equity of the Company: Common stock, $0.001 par value, 250,000,000 shares authorized, 71,333,586 issued and outstanding, respectively 71,334 71,334 Paid-in-capital 18,118,007 18,042,189 Statutory reserves 13,217,217 13,217,217 Retained earnings 129,631,801 126,370,263 Accumulated other comprehensive income 18,277,093 18,262,123 Total shareholders' equity of the Company 179,315,452 175,963,126 Noncontrolling interest 10,161,377 9,812,049 Total equity 189,476,829 185,775,175 Total liabilities and equity $239,362,913 $231,109,708 TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2010 AND 2009 (UNAUDITED) Three months ended March 31, 2010 2009 CASH FLOWS FROM OPERATING ACTIVITIES: Net income $3,603,595 $8,999,799 Adjustments to reconcile net income to cash provided by (used in) operating activities: Provision for doubtful accounts 202,247 (184,568) Depreciation 417,469 544,811 Amortization 83,557 97,143 Interest expense
'/>"/>
SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
2. Tiens Biotech Group (USA) Reports First Quarter Results
3. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
4. eFuture Signs Contract to Provide Tiens Group with Retail Business Management System
5. Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results
6. Cutting-Edge Vaccine Research to be Showcased at AAPS National Biotechnology Conference
7. Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership
8. BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimers Disease
9. TriLink BioTechnologies, Inc. Launches New Website and OligoBuilder(R)
10. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
11. IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... VANCOUVER, British Columbia and ...   DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... data at the 106th Annual Meeting of ... Annual Meeting on the potential for its lead ...
(Date:4/20/2015)... April 20, 2015  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that ... the Company,s Board of Directors. Dr. Jenkins brings ... experience, having built and led teams advancing programs ... and into healthcare systems globally. ...
(Date:4/20/2015)... April 20, 2015  "Everybody is affected by cancer ... patients is frankly brutal. We,ve got to get away ... ward, or witnessed a loved one or friend battling ... the devastation chemotherapy and other treatments cause the human ... to give up and succumb to the disease. Dr. ...
(Date:4/20/2015)... Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical ... for the fourth quarter and full year ended December ... to the fourth quarter 2013) , Quarterly sales ... $22.9 million in the prior year period. Excluding revenue ... of $0.1 million in the fourth quarter of 2014 ...
Breaking Biology Technology:DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18
... The current revision of two European Directives that are ... the safety of patients and enhance their access to ... of a two-day conference, "Haematology and the next European ... doctors, researchers, parliamentarians, patients, organisations and Commission officials. ...
... Veracyte, Inc., a molecular diagnostics company pioneering the emerging ... from researchers at Johns Hopkins University School of Medicine ... Classifier for clarifying inconclusive results on thyroid nodule fine ... save the healthcare system money. According to the economic ...
... 2011 The medical imaging company SyntheticMR ... an order for their magnetic resonance imaging software from ... will be used in clinical practice to monitor the ... software, SyMRI Diagnostics, includes tools to automatically estimate a ...
Cached Biology Technology:Crucial Directives Must be Revised to Protect Patients' Interests and Improve Access to Treatment 2New Data Suggest Veracyte's Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results 2New Data Suggest Veracyte's Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results 3Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 2Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 3
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... researchers are working toward a future in which each ... how oncologists should treat the cancer to obtain the ... patients with prostate cancer should receive extra therapy after ... an indolent disease that does not even require surgery. ...
... working toward a future in which each patient's tumor ... should treat the cancer to obtain the best outcome. ... prostate cancer should receive extra therapy after surgery - ... disease that does not even require surgery. Most patients ...
... have designed a chip ?the GeneChip® Citrus Genome Array ... better manage them. By helping determine which genes are ... are associated with taste, acidic content and disease, for ... rectifying existing problems and making improvements to the fruit. ...
Cached Biology News:AIDS-related cognitive impairment exists in two separate forms 2AIDS-related cognitive impairment exists in two separate forms 3AIDS-related cognitive impairment exists in two separate forms 4AIDS-related cognitive impairment exists in two separate forms 5AIDS-related cognitive impairment exists in two separate forms 6AIDS-related cognitive impairment exists in two separate forms 7Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers 2Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers 3Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers 4Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers 5Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers 6Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers 7UCR researchers design chip that can improve citrus varieties 2UCR researchers design chip that can improve citrus varieties 3
... the joining of two strands of DNA ... of adjacent nucleotides in either a cohesive-ended ... also been shown to catalyze the joining ... RNA strand in a duplex molecule but ...
Bovine Pulmonary Artery Smooth Muscle Cells (BPASMC) (>500,000 cells)...
... monoclonal [E12] to MAP1 Light Chain MAP1A ... physical interactions between microtubules and components of the ... heavy chain subunit and multiple light chain subunits. ... of the light chain subunits and can associate ...
Image Acquisition and documentation system for fluorescent and non-fluorescent gels, membranes, blots, film, plates and assays...
Biology Products: